A phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant ovarian cancer

 

Trial Summary:

This study will evaluate the activity of intraperitoneal bevacizumab in delaying reaccumulation of ascites in patients with chemotherapy resistant ovarian, peritoneal and fallopian tube cancers and symptomatic ascites.

Supported By:

Cancer Australia

Eligibility:

Women with a chemotherapy resistant ovarian, peritoneal or fallopian tube cancer and symptomatic ascites that has recurred within 4 weeks or therapeutic drainage and who are no longer receiving chemotherapy.

Registration ID:

ACTRN12611000801910

Participation:

Australia

Australian Lead Group:

ANZGOG

Status:

Open

Activation Date:

1/11/2013

Chairs:

Katrin Sjoquist

Contact:

rezolve.study@sydney.edu.au